Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Relugolix ATC L02BX04

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

December 31, 2027
Response Due
Active
Status

About this record

The issuing agency did not publish a description for this notice. The full record as GlobalGov received it is below.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedJanuary 16, 2026
Procurement stageActive solicitation
Response dueDecember 31, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Denosumab, Handelsname Xgeva, ATC M05BX04
Germany – Pharmaceutical products – Kontrastmittel wirkstoffübergreifendes Open-House Verfahren für die KV Region Mecklenburg-Vorpommern
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Ebastin (ATC: R06AX22)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Risperidon (ATC-Code N05AX08) eingeschränkt auf die Darreichung Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension.
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion)
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.